We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
05 Sep 2020 - 09 Sep 2020
Virtual Venue

Combined Proteomic/Genomic Method Detects Early Signs of Pancreatic Cancer

By LabMedica International staff writers
Posted on 29 Jul 2020
Print article
Image: There is currently no standard diagnostic tool or method for the early detection of pancreatic cancer. A test that is sensitive and specific enough to detect pancreatic cancer in its earliest stages has the potential of saving many lives (Photo courtesy of Immunovia AB)
Image: There is currently no standard diagnostic tool or method for the early detection of pancreatic cancer. A test that is sensitive and specific enough to detect pancreatic cancer in its earliest stages has the potential of saving many lives (Photo courtesy of Immunovia AB)
A new method that utilized a combined proteomic and genomic approach for profiling serum proteins in solution demonstrated high accuracy for distinguishing samples derived from pancreatic cancer patients and those from healthy controls.

The composition of proteins in the blood serum reflects the current health status of the individual and can, with the right tools, be used to detect early signs of disease, such as an emerging cancer. As the World Health Organization (WHO) has projected that a third of all cancers could be cured if diagnosed already at tumor stage I/II, early diagnosis of cancer would greatly increase the chance of an improved outcome for the patients.

In this regard, investigators at Lund University (Sweden) and colleagues at the biomedical company Immunovia AB (Lund, Sweden) developed a method that combined the specificity of antibodies with the sensitivity of next-generation sequencing (NGS).

This ProMIS technique (Protein detection using Multiplex Immunoassay in Solution) is a streamlined platform for profiling of serum proteins with a solution-based bead array. The assay utilizes antibody fragments (scFv) that were site specifically conjugated to DNA oligonucleotide barcodes, in a 1:1 manner, using a Sortase A-mediated coupling strategy. The barcoded scFvs were mixed with biotinylated serum proteins coupled to streptavidin-coated magnetic beads, and bound antibodies were detected, using NGS allowing for both a multiplex and sensitive read-out.

By working with proteins in solution, the new technique circumvented the inherent technical problems found in conventional biomarker research that utilizies biomatrices, such as. planar- or bead-based arrays.

"We have for years been developing advanced diagnostic approaches for multiplexed analysis of serum proteins, using a single drop of blood, for the purpose of early diagnosis of complex disease, in particular cancer. There is massive amount of information in blood and our combination of proteomics and genomics will open up for rapidly associating early tumor development with protein signatures. This in turn will benefit the patients with a more favorable outcome and overall survival. We are very excited with this novel next generation of biomarker discovery tool," said senior author Dr. Carl Borrebaeck, professor of immunotechnology at Lund University.

The ProMIS technique was described in the July 3, 2020, online edition of the journal Nature Communication Biology.

Related Links:
Lund University
Immunovia AB




Print article

Channels

Industry News

view channel
Image: ChemWell RPR Analyzer (Photo courtesy of Awareness Technology, Inc.)

Awareness Technology Announces ChemWell RPR Analyzer - The Most Significant Innovation in Syphilis Testing in Last 30 Years

Awareness Technology, Inc. (Palm City, FL, USA) has announced the most significant innovation in syphilis testing in the last 30 years with the launch of the ChemWell RPR automated nontreponemal analyzer... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.